Tango Therapeutics, Inc. filed a Form 8-K/A on August 7, 2026, amending its earlier current report to disclose the executed separation agreement with Barbara Weber, M.D., whose employment as Executive Chair ended effective August 3, 2026.

Key Highlights

  • Employment ended: Barbara Weber, M.D.'s employment as Executive Chair ended effective August 3, 2026, and she is deemed to have resigned from all officer and board member positions.
  • Severance pay: Dr. Weber is to receive severance at her current base salary through December 31, 2026, paid in substantially equal installments.
  • COBRA reimbursement: The company will reimburse monthly COBRA premium payments up to December 31, 2026.
  • Equity acceleration: Full acceleration of Dr. Weber's outstanding option and restricted stock unit awards is provided, subject to approval by the Board's Compensation Committee.
  • Option exercise extension: The post-termination exercise period for vested stock options is extended to the earlier of August 3, 2027, or the original expiration date of the applicable option.
  • Pro-rata incentive payment: A pro-rata portion of annual incentive compensation for 2026, if any, will be paid no later than March 15, 2027, at the same time as payments to active employees.

Separation Agreement Terms Between Tango Therapeutics and Barbara Weber, M.D.

According to the filing, Tango Therapeutics (Nasdaq: TNGX) originally reported Dr. Weber's departure in a Form 8-K filed on August 6, 2026. That filing noted the company had offered Dr. Weber certain benefits contingent on her executing and not revoking a separation agreement as outlined in her Amended and Restated Employment Agreement dated January 8, 2026. The 8-K/A amends Item 5.02 of that original report solely to include the terms of the executed Separation Agreement; no other disclosures from the original filing are amended.

The Separation Agreement, executed August 6, 2026, provides severance pay at Dr. Weber's current base salary through December 31, 2026, paid in substantially equal installments, along with reimbursement of monthly COBRA premium payments through the same date. The filing also discloses full acceleration of Dr. Weber's outstanding option and restricted stock unit awards, subject to Compensation Committee approval, and an extension of the post-termination exercise window for her vested options to the earlier of August 3, 2027, or the original expiration date of each applicable option.

Additionally, the filing states Dr. Weber is eligible for a pro-rata portion of 2026 annual incentive compensation, if any, based on Company and individual performance, to be paid no later than March 15, 2027. The company noted that all benefits are conditioned on Dr. Weber not revoking the Separation Agreement as set forth in the Employment Agreement. The filing was signed by Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics.

What Was Disclosed

This 8-K/A amends Tango Therapeutics' August 6, 2026 current report to provide the full terms of the executed separation agreement with former Executive Chair Barbara Weber, M.D., covering severance pay, COBRA reimbursement, equity acceleration, option exercise extension, and a conditional incentive payment.